Ji Hwan Lee1, Jung Woo Han2, Seung Min Hahn2, Chuhl Joo Lyu2, Dong Joon Kim3, Sung Chul Lee4. 1. Department of Ophthalmology, The Institute of Vision Research, Yonsei University College of Medicine, Seoul, Korea. 2. Department of Pediatric Hematology and Oncology, Yonsei University College of Medicine, Seoul, Korea. 3. Department of Radiology, Yonsei University College of Medicine, Seoul, Korea. 4. Department of Ophthalmology, The Institute of Vision Research, Yonsei University College of Medicine, Seoul, Korea. sunglee@yuhs.ac.
Abstract
PURPOSE: We aimed to evaluate the therapeutic effect and complications of combined intravitreal melphalan and intravenous/intra-arterial chemotherapy as a primary approach for retinoblastoma with vitreous seeds. METHODS: In this retrospective case series, eight eyes from eight retinoblastoma patients with vitreous seeds were included. All eyes received 20-30 μg of intravitreal melphalan accompanied by intravenous and intra-arterial chemotherapy. Triple freeze-thaw cryotherapy was performed when withdrawing the needle from the eye to prevent tumor dissemination. RESULTS: Tumors and vitreous seeds regressed in all eyes. The mean number of intravitreal melphalan injections was 3.25 (median 3.50, range 2-4). Globe salvage was attained in seven of eight eyes (87.5 %). Enucleation was performed in one case, in which the pathologic section showed no residual tumor and tumor-free resection margins. Serous retinal detachment was observed in four eyes (50 %), and vitreous hemorrhage developed in two (25 %). Retinal pigment epithelium atrophy or mottling was found in three eyes (37.5 %). There were no cases of extraocular tumor extension or remote metastasis. CONCLUSIONS: Combined intravitreal melphalan and intravenous/intra-arterial chemotherapy was effective for tumor and vitreous seeding control, but vision-threatening complications such as vitreous hemorrhage or serous retinal detachment occurred in half the cases.
PURPOSE: We aimed to evaluate the therapeutic effect and complications of combined intravitreal melphalan and intravenous/intra-arterial chemotherapy as a primary approach for retinoblastoma with vitreous seeds. METHODS: In this retrospective case series, eight eyes from eight retinoblastomapatients with vitreous seeds were included. All eyes received 20-30 μg of intravitreal melphalan accompanied by intravenous and intra-arterial chemotherapy. Triple freeze-thaw cryotherapy was performed when withdrawing the needle from the eye to prevent tumor dissemination. RESULTS:Tumors and vitreous seeds regressed in all eyes. The mean number of intravitreal melphalan injections was 3.25 (median 3.50, range 2-4). Globe salvage was attained in seven of eight eyes (87.5 %). Enucleation was performed in one case, in which the pathologic section showed no residual tumor and tumor-free resection margins. Serous retinal detachment was observed in four eyes (50 %), and vitreous hemorrhage developed in two (25 %). Retinal pigment epithelium atrophy or mottling was found in three eyes (37.5 %). There were no cases of extraocular tumor extension or remote metastasis. CONCLUSIONS: Combined intravitreal melphalan and intravenous/intra-arterial chemotherapy was effective for tumor and vitreous seeding control, but vision-threatening complications such as vitreous hemorrhage or serous retinal detachment occurred in half the cases.
Authors: Carol L Shields; Fairooz P Manjandavida; Sruthi Arepalli; Swathi Kaliki; Sara E Lally; Jerry A Shields Journal: JAMA Ophthalmol Date: 2014-03 Impact factor: 7.389
Authors: Carol L Shields; Carlos G Bianciotto; Pascal Jabbour; Aparna Ramasubramanian; Sara E Lally; Gregory C Griffin; Robert Rosenwasser; Jerry A Shields Journal: Arch Ophthalmol Date: 2011-06-13
Authors: Carol L Shields; Carlos G Bianciotto; Pascal Jabbour; Gregory C Griffin; Aparna Ramasubramanian; Robert Rosenwasser; Jerry A Shields Journal: Arch Ophthalmol Date: 2011-06-13
Authors: Carol L Shields; Aparna Ramasubramanian; Archana Thangappan; Kimberly Hartzell; Ann Leahey; Anna T Meadows; Jerry A Shields Journal: Ophthalmology Date: 2009-01-20 Impact factor: 12.079
Authors: Jesse L Berry; Liya Xu; A Linn Murphree; Subramanian Krishnan; Kevin Stachelek; Emily Zolfaghari; Kathleen McGovern; Thomas C Lee; Anders Carlsson; Peter Kuhn; Jonathan W Kim; David Cobrinik; James Hicks Journal: JAMA Ophthalmol Date: 2017-11-01 Impact factor: 7.389
Authors: Yacoub A Yousef; Mays Al Jboor; Mona Mohammad; Mustafa Mehyar; Mario D Toro; Rashed Nazzal; Qusai H Alzureikat; Magdalena Rejdak; Mutasem Elfalah; Iyad Sultan; Robert Rejdak; Maysa Al-Hussaini; Ibrahim Al-Nawaiseh Journal: Front Pharmacol Date: 2021-07-12 Impact factor: 5.810